NCT04498377View on ClinicalTrials.gov

Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

January 26, 2021

Primary Completion Date

March 24, 2021

Study Completion Date

March 24, 2021

Conditions
Covid19
Interventions
BIOLOGICAL

F-652

IL-22 fusion protein administered intravenously

BIOLOGICAL

Placebo

Placebo administered intravenously

Trial Locations (1)

70112

Tulane University School of Medicine, New Orleans

Sponsors
All Listed Sponsors
lead

EVIVE Biotechnology

INDUSTRY